Federal Circuit Affirms Anticipation of COVID-19 Antiviral Patent, Holding That a Provisional’s “C2” Disclosure Cannot Support a “C1” Claim for Priority
06/30/2026
On June 23, 2026, the U.S. Court of Appeals for the Federal Circuit (Judges Lourie, Bryson, and Chen) affirmed a decision of the U.S. District Court for the District of Massachusetts granting summary judgment that all claims of Enanta Pharmaceuticals, Inc.’s U.S. Patent No. 11,358,953 (“the ’953 patent”) are invalid as anticipated. Enanta Pharms., Inc. v. Pfizer Inc., No. 2025-1427 (Fed. Cir. June 23, 2026).
